Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399219 | 0.84 | HCAR2 (0.33) | SLC22A6TDP1SMN1; SMN2 | |
| SCHEMBL8307598 | 0.83 | ALDH1A1 (0.41) | SLC22A6TDP1SMN1; SMN2MAPTALOX15 | |
| SCHEMBL5915068 | 0.82 | SLC22A6 (0.38) | SLC22A6TDP1SMN1; SMN2MAPTALOX15 | |
| SCHEMBL1480202 | 0.80 | KMT2A (0.37) | SLC22A6TDP1SMN1; SMN2MAPTALOX15 | |
| SCHEMBL6057628 | 0.80 | KMT2A (0.37) | SLC22A6TDP1SMN1; SMN2MAPTALOX15 | |
| SCHEMBL27476095 | 0.80 | SLC22A6 (0.36) | SLC22A6TDP1SMN1; SMN2MAPTALOX15 | |
| SCHEMBL11219831 | 0.77 | ALDH1A1 (0.42) | TDP1LMNATSHR | |
| SCHEMBL8625996 | 0.75 | FOLH1 (0.44) | MAPTLMNAFOLH1 | |
| SCHEMBL5246516 | 0.75 | SLC22A6 (0.32) | SLC22A6TDP1SMN1; SMN2 | |
| SCHEMBL640316 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116643042-A | Thrombomodulin Chemiluminescence Detection Kit | 上海太阳生物技术有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-116643042-A | Thrombomodulin Chemiluminescence Detection Kit | 上海太阳生物技术有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-8491929-B2 | Bioadhesive polymers | VAUNNEX INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110086095-A1 | Bioadhesive Polymers | Spherics, Inc (MA) | 2011-04-14 | — | — | US | disclosed |
| US-20100316712-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| US-7784919-B2 | Methods for improving flow through fluidic channels | LEXMARK INTERNATIONAL, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-2063867-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | Combinatorx, Incorporated (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008079404-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1901720-A2 | IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT | Spherics, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008002471-A2 | EROSION-STABILIZED BIOADHESIVE POLYMERS FUNCTIONALIZED OR BLENDED WITH CATECHOL AND DERIVATIVES THEREOF | SPHERICS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070148238-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070076058-A1 | Methods for improving flow through fluidic channels | LEXMARK INTERNATIONAL, INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2007002318-A2 | BIOADHESIVE POLYMERS | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002516-A2 | IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003621-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086095-A1 | Bioadhesive Polymers | CD44, EPCAM, ABCG2 | SLC22A6 701/4885TDP1 2516/4885SMN1; SMN2 2825/4885 |
| US-20100316712-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | PARK7, SNCA, COMT | SLC22A6 1589/4885TDP1 402/4885SMN1; SMN2 6/4885 |
| US-20070148238-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | SLC22A6 537/4885TDP1 416/4885SMN1; SMN2 6/4885 |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | SLC22A6 537/4885TDP1 416/4885SMN1; SMN2 6/4885 |
| US-20070003621-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | SLC22A6 537/4885TDP1 416/4885SMN1; SMN2 6/4885 |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | SLC22A6 537/4885TDP1 416/4885SMN1; SMN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.